Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.
Konstantin Zakashansky, MD
Advertisement
Articles by Konstantin Zakashansky, MD
Konstantin Zakashansky, MD, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.
Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.
Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.
Advertisement
Latest Updated Articles
Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian CancerPublished: June 3rd 2020 | Updated:
Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian CancerPublished: June 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5